Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Prof Jayandharan Rao has received his PhD in TN MGR medical University during the period of 2006. Currently, he is working as working as an Associate Professor at the Christian Medical College, Vellore, India. During this past 8 years he has been actively involved in translational research to develop gene therapy using adeno-associated virus (AAV) vectors. Based on this research he has received several awards and honors, such as: Swarnajayanthi award from Department of Science and Technology (2011), Innovative young biotechnologist award from Department of Biotechnology (2010), Eberhard Mammen Young Investigator award (2010) and Bayer Early career investigator award from Bayer Inc USA (2010) in recognition of his expertise in gene therapy research. His work has been invited to be presented in several international events including World federation of hemophilia congress in Vancouver, Bangkok, Paris, Chicago. He is serving as an expert reviewer for journals like Molecular Therapy, J of Thrombosis Haemostasis, FEBS journal, Gene Therapy etc. He has also authored 53 research articles/books. He is a member of American Society of Gene and Cell Therapy, International society of thrombosis and hemostasis and world federation of hemophilia. He has been honoured as Invited meber in Hematology and Immunology gene and cell therapy committee, ASGCT and Lab sciences committee, World Federation of Hemophilia.
The collective experience with Adeno-associated virus (AAV) vector mediated human gene therapy trials so far, have clearly pointed to the need for substantial improvement in the efficiency of AAV mediated transgene expression as well as the need to attenuate the capsid-or transgene specific innate or adaptive immune responses against these vectors to achieve successful long-term gene transfer. My research is thus focused on dissecting out the basic biology of AAV life-cycle by understanding the interactions between AAV and various host cellular proteins, use this knowledge to design strategies to either augment the efficiency of gene transfer or intervene with (immune response) processes which are detrimental to AAV's survival, yet maintain the safety of these interventionist strategies to the host cellular environment and finally authenticate their use in therapeutic models such as pre-clinical animal models of haemophilia and leukemia.